CN109008959A - Internal Medicine-Oncology chemotherapy side effect intelligent decision system - Google Patents
Internal Medicine-Oncology chemotherapy side effect intelligent decision system Download PDFInfo
- Publication number
- CN109008959A CN109008959A CN201810627718.1A CN201810627718A CN109008959A CN 109008959 A CN109008959 A CN 109008959A CN 201810627718 A CN201810627718 A CN 201810627718A CN 109008959 A CN109008959 A CN 109008959A
- Authority
- CN
- China
- Prior art keywords
- chemotherapy
- side effect
- information
- patient
- doctor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 152
- 230000000694 effects Effects 0.000 title claims abstract description 120
- 238000012544 monitoring process Methods 0.000 claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
- 238000009104 chemotherapy regimen Methods 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- 238000007086 side reaction Methods 0.000 claims description 22
- 230000003907 kidney function Effects 0.000 claims description 10
- 210000001185 bone marrow Anatomy 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 7
- 230000001629 suppression Effects 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims 2
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 24
- 238000009472 formulation Methods 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 5
- 238000004904 shortening Methods 0.000 abstract description 4
- 230000007306 turnover Effects 0.000 abstract description 4
- 230000003908 liver function Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000003870 Drug Overdose Diseases 0.000 description 2
- 206010033296 Overdoses Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 231100000725 drug overdose Toxicity 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Data Mining & Analysis (AREA)
- Primary Health Care (AREA)
- Artificial Intelligence (AREA)
- Databases & Information Systems (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明涉及肿瘤治疗技术领域，具体涉及一种化疗智能辅助方法及系统。包括：副反应监测，在监测到患者出现化疗副反应并且所述化疗副反应的反应程度超过预设等级时，输出所述化疗副反应的相关信息至所述患者的医生账户；副反应查询，根据检索信息在化疗副反应数据库中查询相关的化疗副反应信息，并且以数据图表的形式输出查询结果；化疗方案辅助制定，根据患者资料计算化疗药物剂量，并且监控化疗医嘱中的化疗药物剂量。缩短化疗平均住院日、加快病床周转，能够充分运用有限的医疗卫生资源，降低病人医疗费用，同时也能提高医院经济效益。The invention relates to the technical field of tumor treatment, in particular to an intelligent auxiliary method and system for chemotherapy. Including: monitoring of side effects, when monitoring side effects of chemotherapy in patients and the degree of side effects of side effects of chemotherapy exceeds a preset level, output relevant information about side effects of chemotherapy to the doctor account of the patient; query side effects, According to the search information, query relevant chemotherapy side effect information in the chemotherapy side effect database, and output the query results in the form of data charts; assist in the formulation of chemotherapy regimens, calculate the dose of chemotherapy drugs based on patient information, and monitor the dose of chemotherapy drugs in the chemotherapy doctor's order. Shortening the average length of hospitalization for chemotherapy and speeding up the turnover of hospital beds can make full use of limited medical and health resources, reduce the medical expenses of patients, and improve the economic benefits of the hospital at the same time.
Description
技术领域technical field
本发明涉及肿瘤治疗技术领域，具体涉及一种肿瘤内科化疗副反应智能决策系统。The invention relates to the technical field of tumor treatment, in particular to an intelligent decision-making system for side effects of chemotherapy in internal medicine of tumors.
背景技术Background technique
肿瘤患者在化疗过程中容易出现各种化疗副反应，比如骨髓抑制，肝功能损害，肾功能损害等。主管医生以往都是通过个人经验和手工记录来监测患者化疗后副反应，经常出现响应不及时，监测不到位的情况。导致患者的化疗住院的周期较长，造成患者和医院资源的浪费。Cancer patients are prone to various chemotherapy side effects during chemotherapy, such as bone marrow suppression, liver function damage, renal function damage, etc. In the past, the doctor in charge used personal experience and manual records to monitor the side effects of patients after chemotherapy. Often, the response was not timely and the monitoring was not in place. This leads to a longer period of hospitalization for chemotherapy of patients, resulting in a waste of resources for patients and hospitals.
发明内容Contents of the invention
本发明为解决上述技术问题， 本发明提供一种肿瘤内科化疗副反应智能决策方法，其特征在于，包括：In order to solve the above technical problems, the present invention provides an intelligent decision-making method for side effects of chemotherapy in oncology, which is characterized in that it includes:
副反应监测，在监测到患者出现化疗副反应并且所述化疗副反应的反应程度超过预设等级时，输出所述化疗副反应的相关信息至所述患者的医生账户；Monitoring of side effects, outputting relevant information about side effects of chemotherapy to the doctor account of the patient when it is monitored that side effects of chemotherapy occur in the patient and the degree of side effects of side effects of chemotherapy exceeds a preset level;
副反应查询，根据检索信息在化疗副反应数据库中查询相关的化疗副反应信息，并且以数据图表的形式输出查询结果；Side reaction query, query relevant chemotherapy side reaction information in the chemotherapy side reaction database according to the search information, and output the query results in the form of data charts;
化疗方案辅助制定，根据患者资料计算化疗药物剂量，并且监控化疗医嘱中的化疗药物剂量；Auxiliary formulation of chemotherapy regimens, calculation of chemotherapy drug doses based on patient data, and monitoring of chemotherapy drug doses in chemotherapy orders;
其中，所述化疗副反应包括骨髓抑制、肝功能损害、肾功能损害中的一种或者多种。Wherein, the side effects of chemotherapy include one or more of bone marrow suppression, liver function damage, and kidney function damage.
上述技术方案在患者出现化疗副反应的前端及后端都能够做到及时处理，并且根据患者信息对之后的化疗方案做出智能修正与决策，为医生和患者服务。降低了患者住院期间发生化疗副反应的比例降低，使得患者减少辅助用药使用占比，同时患者的住院时间也因此缩短。肿瘤内科的平均住院日及平均住院费用呈下降趋势。缩短平均住院日、加快病床周转，能够充分运用有限的医疗卫生资源，降低病人医疗费用，同时也能提高医院经济效益。The above-mentioned technical solutions can handle the front-end and back-end of chemotherapy side effects in patients in a timely manner, and make intelligent corrections and decisions on subsequent chemotherapy plans based on patient information, serving doctors and patients. It reduces the proportion of side effects of chemotherapy during the hospitalization of patients, reduces the proportion of patients using adjuvant drugs, and shortens the length of hospitalization of patients. The average hospitalization days and average hospitalization expenses of the medical oncology department showed a downward trend. Shortening the average length of stay and speeding up the turnover of hospital beds can make full use of limited medical and health resources, reduce the medical expenses of patients, and improve the economic benefits of the hospital at the same time.
作为优选，输出所述化疗副反应的相关信息至所述患者的医生账户是指，在所述医生账户的界面以弹窗的形式输出所述化疗副反应的相关信息。Preferably, outputting the information about side effects of chemotherapy to the patient's doctor account refers to outputting the information about side effects of chemotherapy in the form of a pop-up window on the interface of the doctor account.
作为优选，所述化疗副反应信息，包括患者化疗期间的化疗副反应指标和肿瘤标志物指标。Preferably, the information on side effects of chemotherapy includes indicators of side effects of chemotherapy and indicators of tumor markers during chemotherapy of patients.
作为优选，所述患者资料包括患者的所述化疗副反应信息，以及患者的身高信息、体重信息、体表面积信息中的一种或者多种。Preferably, the patient information includes the patient's side reaction information of chemotherapy, and one or more of the patient's height information, weight information, and body surface area information.
作为优选，监控化疗医嘱中的化疗药物剂量是指，在所述化疗药物超量时输出警告信息、以及在所述化疗药物超量程度大于预设条件时禁止开具所述化疗医嘱。Preferably, monitoring the chemotherapy drug dose in the chemotherapy doctor's order refers to outputting a warning message when the chemotherapy drug is overdose, and prohibiting issuing the chemotherapy doctor's order when the chemotherapy drug overdose is greater than a preset condition.
本发明还提供了一种肿瘤内科化疗副反应智能决策系统，其特征在于：The present invention also provides an intelligent decision-making system for side effects of chemotherapy in medical oncology, characterized in that:
副反应监测模块，用于在监测到患者出现化疗副反应并且所述化疗副反应的反应程度超过预设等级时，输出所述化疗副反应的相关信息至所述患者的医生账户；The side effect monitoring module is used to output information about side effects of chemotherapy to the doctor account of the patient when it is monitored that side effects of chemotherapy occur in the patient and the degree of side effects of side effects of chemotherapy exceeds a preset level;
副反应查询模块，用于根据检索信息在化疗副反应数据库中查询相关的化疗副反应信息，并且以数据图表的形式输出查询结果；A side reaction query module is used to query relevant chemotherapy side reaction information in the chemotherapy side reaction database according to the retrieval information, and output the query results in the form of data charts;
化疗方案辅助制定模块，用于根据患者资料计算化疗药物剂量，并且监控化疗医嘱中的化疗药物剂量；Chemotherapy program auxiliary formulating module, used to calculate the dose of chemotherapy drugs according to the patient's data, and monitor the dose of chemotherapy drugs in the chemotherapy doctor's order;
其中，所述化疗副反应包括骨髓抑制、肝功能损害、肾功能损害中的一种或者多种。Wherein, the side effects of chemotherapy include one or more of bone marrow suppression, liver function damage, and kidney function damage.
上述技术方案在患者出现化疗副反应的前端及后端都能够做到及时处理，并且根据患者信息对之后的化疗方案做出智能修正与决策，为医生和患者服务。降低了患者住院期间发生化疗副反应的比例降低，使得患者减少辅助用药使用占比，同时患者的住院时间也因此缩短。肿瘤内科的平均住院日及平均住院费用呈下降趋势。缩短平均住院日、加快病床周转，能够充分运用有限的医疗卫生资源，降低病人医疗费用，同时也能提高医院经济效益。The above-mentioned technical solutions can handle the front-end and back-end of chemotherapy side effects in patients in a timely manner, and make intelligent corrections and decisions on subsequent chemotherapy plans based on patient information, serving doctors and patients. It reduces the proportion of side effects of chemotherapy during the hospitalization of patients, reduces the proportion of patients using adjuvant drugs, and shortens the length of hospitalization of patients. The average hospitalization days and average hospitalization expenses of the medical oncology department showed a downward trend. Shortening the average length of stay and speeding up the turnover of hospital beds can make full use of limited medical and health resources, reduce the medical expenses of patients, and improve the economic benefits of the hospital at the same time.
作为优选，所述副反应检测模块包括告警单元；所述告警单元，在所述医生账户的界面以弹窗的形式输出所述化疗副反应的相关信息。Preferably, the side reaction detection module includes an alarm unit; the alarm unit outputs information related to side effects of chemotherapy in the form of a pop-up window on the interface of the doctor account.
作为优选，所述化疗副反应信息，包括患者化疗期间的化疗副反应指标和肿瘤标志物指标。Preferably, the information on side effects of chemotherapy includes indicators of side effects of chemotherapy and indicators of tumor markers during chemotherapy of patients.
作为优选，所述患者资料包括患者的所述化疗副反应信息，以及患者的身高信息、体重信息、体表面积信息中的一种或者多种。Preferably, the patient information includes the patient's side reaction information of chemotherapy, and one or more of the patient's height information, weight information, and body surface area information.
作为优选，所述化疗方案辅助制定模块，包括告警单元；所述告警单元，在所述化疗药物超量时输出警告信息；所述告警单元，在所述化疗药物超量程度大于预设条件时禁止开具所述化疗医嘱。Preferably, the chemotherapeutic plan auxiliary formulation module includes an alarm unit; the alarm unit outputs a warning message when the chemotherapy drug is overdose; the alarm unit outputs a warning message when the chemotherapy drug overdose is greater than a preset condition Orders for said chemotherapy are prohibited.
具体实施方式Detailed ways
下面将结合附图对本发明的实施方式进行详细描述。Embodiments of the present invention will be described in detail below with reference to the accompanying drawings.
本具体实施例仅仅是对本发明的解释，其并不是对发明的限制，本领域技术人员在阅读完本说明书后可以根据需要对本实施例做出没有创造性贡献的修改，但只要在本发明的权利要求范围内都收到专利法的保护。This specific embodiment is only an explanation of the present invention, and it is not a limitation of the invention. Those skilled in the art can make modifications to this embodiment without creative contribution as required after reading this specification, but as long as they are within the rights of the present invention The scope of the requirements are protected by the patent law.
实施例一Embodiment one
一种肿瘤内科化疗副反应智能决策系统，包括副反应检测模块、副反应查询模块和化疗方案辅助指定模块。An intelligent decision-making system for side effects of chemotherapy in medical oncology, including a side reaction detection module, a side reaction query module, and a chemotherapy scheme auxiliary designation module.
一.副反应监测模块1. Side reaction monitoring module
副反应检测模块，用于在监测到患者出现化疗副反应并且在化疗副反应的反应程度超过预设等级时，输出所述化疗副反应的相关信息至所述患者的医生账户。其中，所述化疗副反应包括骨髓抑制、肝功能损害、肾功能损害中的一种或者多种。包括告警单元。The side effect detection module is used to output information about side effects of chemotherapy to the doctor account of the patient when it is monitored that side effects of chemotherapy occur in the patient and the degree of side effects of chemotherapy exceeds a preset level. Wherein, the side effects of chemotherapy include one or more of bone marrow suppression, liver function damage, and kidney function damage. Includes alarm unit.
反应监测模块能够主动监测患者的化疗检查结果，或者能够被动接收输入的患者的化疗检查结果。当反应检测模块监测到患者的化疗检查结果出现异常值时，判断该患者出现化疗副反应。The response monitoring module can actively monitor the patient's chemotherapy test results, or can passively receive the input patient's chemotherapy test results. When the response detection module monitors that the patient's chemotherapy test results have abnormal values, it is determined that the patient has a chemotherapy side effect.
反应监测模块包括评估单元，该评估单元能够根据WHO（世界卫生组织）关于化疗后副反应的标准对患者的化疗副反应的反应程度进行评估。例如，在患者出现度骨髓抑制、肝功能损害、肾功能损害时，评估患者的化疗副反应程度为二级；在患者出现III度以上骨髓抑制、肝功能损害、肾功能损害时，评估患者的化疗副反应程度为三级。化疗副反应程度越大、等级越高。The response monitoring module includes an evaluation unit, which can evaluate the degree of response of the patient's side effects of chemotherapy according to WHO (World Health Organization) standards on side effects after chemotherapy. For example, when a patient has a degree of myelosuppression, liver function damage, or renal function damage, the degree of side effects of chemotherapy is assessed as grade two; The degree of side effects of chemotherapy was grade three. The greater the degree of chemotherapy side effects, the higher the grade.
反应监测模块包括报警单元，该报警单元能够输出关于该患者的化疗副反应的相关信息。例如，报警单元可以根据评估单元的评估结果，在该患者的医生（主管医生/主治医生）账户的界面中实时的以弹窗的形式输出关于该化疗副反应的相关信息，并为该信息标注2个星号以表示其化疗副反应等级为二级。或者，在该患者的医生（主管医生/主治医生）账户的界面中实时的以弹窗的形式输出关于该化疗副反应的相关信息，并为该信息标注3个星号以表示其化疗副反应等级为三级。医生账户界面可以是内嵌在化疗智能辅助系统中的医生的账户界面；也可以是独立于化疗智能辅助系统的某一主管医生病历系统。通过告警单元的弹窗提醒，能够让患者的主管医生及时获悉患者产生了化疗副反应，使得医生能够及时的查看患者的化疗副反应情况（例如，化疗副反应等级），根据该化疗副反应信息及时的响应并处理。可以缩短主管医生对化疗后副反应的响应时间，减少患者副反应的持续时间。The reaction monitoring module includes an alarm unit capable of outputting relevant information about side effects of chemotherapy of the patient. For example, the alarm unit can output relevant information about the side effects of chemotherapy in the form of a pop-up window in real time in the interface of the patient's doctor (doctor in charge/attending doctor) account according to the evaluation result of the evaluation unit, and mark the information Two asterisks indicate that the side effects of chemotherapy are grade two. Or, in the interface of the patient's doctor (doctor in charge/doctor in charge) account, output relevant information about the side effects of chemotherapy in the form of a pop-up window in real time, and mark the information with 3 asterisks to indicate side effects of chemotherapy The grade is three. The doctor account interface can be the doctor's account interface embedded in the chemotherapy intelligent assistance system; it can also be a doctor's medical record system independent of the chemotherapy intelligent assistance system. Through the pop-up window reminder of the alarm unit, the doctor in charge of the patient can be notified in time that the patient has a side effect of chemotherapy, so that the doctor can check the side effect of the patient's chemotherapy in time (for example, the grade of the side effect of chemotherapy), according to the information of the side effect of chemotherapy Respond and deal with it in a timely manner. It can shorten the response time of the doctor in charge to the side effects after chemotherapy, and reduce the duration of the side effects of the patients.
二.副反应查询模块2. Side reaction query module
副反应监测模块能够将监测到的患者的化疗副反应信息存储至化疗副反应数据库中。副反应查询模块用于根据检索信息在化疗副反应数据库中查询相关的化疗副反应信息，并且以数据图表的形式输出查询结果。The side effect monitoring module can store the monitored chemotherapy side effect information of patients into the chemotherapy side effect database. The side reaction query module is used to query relevant chemotherapy side reaction information in the chemotherapy side reaction database according to the retrieval information, and output the query results in the form of data charts.
可以通过副反应查询模块完整地检测化疗副反应的总体趋势。医生通过设定查询关键字和搜索逻辑，形成检索式等检索信息。副反应查询模块根据输入的检索式在化疗副反应数据库中进行查询，可以准确定位到医生重点关注的某个或某一群体患者。例如，医生可以根据患者治疗时间、患者姓名、年龄、性别等患者相关信息作为关键词搜索特定的目标患者或目标患者群体；还可以根据患者使用的化疗药物搜索出特定化疗方案的目标患者。患者的化疗副反应信息包括患者在化疗期间的骨髓造血功能指标、肝功能指标、肾功能指标等化疗副反应相关指标及肿瘤标志物指标等数据。副反应检测模块能够将查询到的患者的化疗副反应信息通过诸如折线图等数据图标的形式输出。例如，通过折线图表示的查询结果，能够体现患者在化疗过程中的整体趋势。而医生通过完整监测患者副反应及肿瘤指标的整体趋势，医生可以提前对体质较差，容易出现副反应的病人提前做出处理。比如，出院带护肝药、入院前先升白细胞等。即通过在副反应前端进行提前处理，减少患者出现副反应的次数。The overall trend of chemotherapy side effects can be completely detected through the side effect query module. Doctors search for information by setting query keywords and search logic, forming search formulas, etc. The side effect query module searches the side effect database of chemotherapy according to the input search formula, and can accurately locate a patient or a certain group of patients that doctors focus on. For example, doctors can search for specific target patients or target patient groups based on patient treatment time, patient name, age, gender and other patient-related information as keywords; they can also search for target patients for specific chemotherapy regimens based on the chemotherapy drugs used by patients. The chemotherapy side effect information of the patient includes the bone marrow hematopoietic function index, liver function index, kidney function index and other chemotherapy side effect related indexes and tumor marker indexes of the patient during chemotherapy. The side effect detection module can output the queried patient's chemotherapy side effect information in the form of data icons such as line charts. For example, the query results represented by a line graph can reflect the overall trend of patients during chemotherapy. By completely monitoring the side effects of patients and the overall trend of tumor indicators, doctors can treat patients with poor physical fitness and prone to side effects in advance. For example, take liver-protecting drugs when discharged from the hospital, and increase white blood cells before admission. That is, through early treatment at the front end of side effects, the number of side effects in patients can be reduced.
可以通过副反应查询模块统计科室整体副反应情况。反应查询模块可以根据输入的检索信息，统计一段特定时间内出现副反应病人的整体概况，并且将查询结果用诸如饼图或折线图等数据图标的形式输出并展示给医生，以反映科室医生在处理化疗副反应的过程中应重点关注的对象和需要改进的地方。The overall side effects of the department can be counted through the side effects query module. The response query module can count the overall profile of patients with side effects in a specific period of time according to the input retrieval information, and output and display the query results to doctors in the form of data icons such as pie charts or line charts to reflect the status of doctors in the department. What should be focused on and what needs to be improved in the process of dealing with side effects of chemotherapy.
进一步的，副反应查询模块输出的数据图表具有数据钻取的功能，医生通过点击数据图表中的相应部分，可从科室整体化疗患者群体，定位到出现特定副反应的患者群体，并且还能够再进一步定位到某个特定患者。使得医生可以更好地分析科室患者的化疗副反应整体情况，有利于改进医生临床决策，还可以满足科研统计需求。Furthermore, the data chart output by the side effect query module has the function of data drilling. By clicking the corresponding part in the data chart, the doctor can locate the patient group with specific side effects from the overall chemotherapy patient group in the department, and can further Further target a specific patient. It enables doctors to better analyze the overall situation of chemotherapy side effects of patients in the department, which is conducive to improving doctors' clinical decision-making and can also meet the statistical needs of scientific research.
三.化疗方案辅助制定模块3. Auxiliary formulation module of chemotherapy regimen
化疗方案辅助制定模块用于根据患者资料计算化疗药物剂量，并且监控化疗医嘱中的化疗药物剂量。Chemotherapy program assistant formulating module is used to calculate the dosage of chemotherapy drugs according to the patient's data, and monitor the dosage of chemotherapy drugs in the chemotherapy doctor's order.
医生可以基于化疗智能辅助系统为患者开具化疗医嘱。化疗方案辅助制定模块能够根据患者资料自动计算化疗药物剂量。化疗方案辅助制定模块根据患者的身高、体重、体表面积、以及存储在化疗副反应数据库中的化疗副反应信息中的一种或者多种精确计算出患者的化疗药物剂量，供医生参考。另外，化疗方案辅助制定模块还能在医生出具化疗医嘱时，对该化疗医嘱中采用的化疗药物计量进行审核。例如，化疗方案辅助指定模块能够纳入患者化疗副反应相关信息中的相关检查结果，根据NCCN（美国国立综合癌症网络）等肿瘤学相关指南及中国药典记载的相关禁忌，引用相关公式，综合考虑患者的骨髓造血功能、肝肾功能等指标对化疗医嘱中的化疗药物剂量进行评估。当化疗药物剂量超量时，通过其告警单元输出告警信息，提醒医生采用的化疗药物剂量已超量；如果化疗药物剂量严重超标（即采用的化疗药物超量程度大于预设的最大使用量时）禁止医生开具出该化疗医嘱。例如，告警模块在开具医嘱的界面中以弹窗的形式输出超标化疗药物剂量的相关信息。Doctors can issue chemotherapy orders for patients based on the chemotherapy intelligent assistance system. The Chemotherapy Program Auxiliary Formulating Module can automatically calculate the dose of chemotherapy drugs based on patient data. The auxiliary chemotherapy plan formulation module accurately calculates the dose of chemotherapy drugs for the patient based on one or more of the patient's height, weight, body surface area, and chemotherapy side-effect information stored in the chemotherapy side-effect database for reference by doctors. In addition, the chemotherapy plan auxiliary formulating module can also review the dosage of chemotherapy drugs used in the chemotherapy doctor's order when the doctor issues the chemotherapy doctor's order. For example, the auxiliary chemotherapy regimen designation module can include the relevant examination results in the information about side effects of chemotherapy in patients. According to NCCN (National Comprehensive Cancer Network) and other oncology-related guidelines and relevant contraindications recorded in the Chinese Pharmacopoeia, relevant formulas are cited to comprehensively consider patients The dosage of chemotherapy drugs in the chemotherapy doctor's order was evaluated by indicators such as bone marrow hematopoietic function, liver and kidney function. When the dose of chemotherapeutic drugs is overdose, the alarm unit will output an alarm message to remind the doctor that the dose of chemotherapeutic drugs used has been overdose; ) prohibits the doctor from issuing the chemotherapy order. For example, the alarm module outputs relevant information about the dosage of chemotherapy drugs exceeding the standard in the form of a pop-up window in the interface for issuing a doctor's order.
通过本发明的化疗智能辅助系统，在患者出现化疗副反应的前端及后端都做到及时处理，用信息化系统达到辅助诊疗的目的。能够降低因患者住院期间发生化疗副反应的比例，使得患者减少辅助用药使用占比，同时患者的住院时间也因此缩短。并且能够降低肿瘤内科的平均住院日及平均住院费用。平均住院日的缩短，能够进一步加快病床周转，使得我们能够充分运用有限的医疗卫生资源，降低病人医疗费用，同时也能提高医院经济效益。Through the chemotherapy intelligent auxiliary system of the present invention, both the front end and the back end of chemotherapy side effects in patients can be dealt with in time, and the information system can be used to achieve the purpose of auxiliary diagnosis and treatment. It can reduce the proportion of side effects of chemotherapy due to patients' hospitalization, so that patients can reduce the proportion of adjuvant drugs used, and the hospitalization time of patients is also shortened. And it can reduce the average length of hospital stay and the average hospitalization cost of medical oncology. The shortening of the average hospitalization day can further speed up the turnover of hospital beds, enable us to make full use of limited medical and health resources, reduce the medical expenses of patients, and at the same time improve the economic benefits of the hospital.
基于上述肿瘤内科化疗副反应智能决策系统对化疗进行智能辅助决策的步骤为：Based on the above-mentioned intelligent decision-making system for side effects of chemotherapy in medical oncology, the steps for intelligent auxiliary decision-making for chemotherapy are as follows:
Step1：肿瘤患者入院后，常规行化疗前检查：如抽血查血常规、肝肾功能等。Step1: After the cancer patients are admitted to the hospital, routine pre-chemotherapy checks are performed: such as blood test, liver and kidney function, etc.
Step2：副反应检测模块在检查结果出现异常值时，利用弹窗提醒及时通知主管医生或值班医生，使患者第一时间得到处理。Step2: When the side reaction detection module has an abnormal value in the inspection result, it will use the pop-up window to notify the doctor in charge or the doctor on duty in time, so that the patient can be treated as soon as possible.
Step3：主管医生可使用副反应查询模块搜索该患者在一定时间段内各项指标的变化情况，综合评估患者治疗期间身体素质及对化疗敏感程度，以调整化疗药物的使用剂量。Step3: The doctor in charge can use the side effect query module to search for the changes of various indicators of the patient within a certain period of time, comprehensively evaluate the patient's physical fitness and sensitivity to chemotherapy during treatment, and adjust the dosage of chemotherapy drugs.
Step4：主管医生给患者开具化疗医嘱时，化疗方案辅助制定模块能够根据患者资料及本次的检查结果自动计算化疗药物剂量。医生可采纳计算结果或根据患者具体情况调整化疗药物剂量，但当化疗剂量超量时，将会弹出警告提醒，严重超标时表现为7级处方，不予通过。Step4: When the doctor in charge issues a chemotherapy order to the patient, the auxiliary chemotherapy plan formulation module can automatically calculate the dose of chemotherapy drugs based on the patient's information and the results of this examination. Doctors can adopt the calculation results or adjust the dose of chemotherapy drugs according to the specific situation of the patient. However, when the chemotherapy dose exceeds the dose, a warning reminder will pop up. If it is seriously exceeded, it will be a level 7 prescription and will not be approved.
Step5： 患者出院后，科室也能通过副反应查询模块查询一段时间以来本科室不同癌种或化疗方案的患者出现化疗副反应的整体情况，有利于改进医生临床决策，满足科研统计需求。Step5: After the patient is discharged from the hospital, the department can also query the overall situation of chemotherapy side effects of patients with different cancer types or chemotherapy regimens in the department for a period of time through the side effect query module, which is conducive to improving doctors' clinical decision-making and meeting the needs of scientific research statistics.
虽然描述了本发明的实施方式，但是本领域普通技术人员可以在所附权利要求的范围内做出各种变形或修改。Having described the embodiments of the present invention, various variations or modifications may be made by those skilled in the art within the scope of the appended claims.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810627718.1A CN109008959A (en) | 2018-06-19 | 2018-06-19 | Internal Medicine-Oncology chemotherapy side effect intelligent decision system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810627718.1A CN109008959A (en) | 2018-06-19 | 2018-06-19 | Internal Medicine-Oncology chemotherapy side effect intelligent decision system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109008959A true CN109008959A (en) | 2018-12-18 |
Family
ID=64609899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810627718.1A Pending CN109008959A (en) | 2018-06-19 | 2018-06-19 | Internal Medicine-Oncology chemotherapy side effect intelligent decision system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109008959A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112349371A (en) * | 2020-11-18 | 2021-02-09 | 南通市第一人民医院 | Chemotherapy patient drug record evaluation method and device |
| CN119361072A (en) * | 2024-12-27 | 2025-01-24 | 山东衡昊信息技术有限公司 | An electronic management system and method for the treatment process and follow-up of childhood malignant tumors |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833599A (en) * | 1993-12-13 | 1998-11-10 | Multum Information Services | Providing patient-specific drug information |
| US20080033894A1 (en) * | 2006-04-17 | 2008-02-07 | Siemens Medical Solutions Usa, Inc. | Prognosis Modeling From One or More Sources of Information |
| CN102004863A (en) * | 2010-12-15 | 2011-04-06 | 中国人民解放军第四军医大学 | Clinical safe and reasonable administration decision supporting method |
| CN103279668A (en) * | 2013-05-31 | 2013-09-04 | 浙江大学 | Quantitative evaluation system for cancer chemoradiotherapy standard conformity |
| CN106372428A (en) * | 2016-08-31 | 2017-02-01 | 杭州逸曜信息技术有限公司 | Detection method of untoward effect information of medicine clinic abnormal indexes |
| CN106874677B (en) * | 2017-02-20 | 2020-05-19 | 上海智眠信息科技有限公司 | Remote auxiliary medical method and device and medical advice platform system |
-
2018
- 2018-06-19 CN CN201810627718.1A patent/CN109008959A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833599A (en) * | 1993-12-13 | 1998-11-10 | Multum Information Services | Providing patient-specific drug information |
| US20080033894A1 (en) * | 2006-04-17 | 2008-02-07 | Siemens Medical Solutions Usa, Inc. | Prognosis Modeling From One or More Sources of Information |
| CN102004863A (en) * | 2010-12-15 | 2011-04-06 | 中国人民解放军第四军医大学 | Clinical safe and reasonable administration decision supporting method |
| CN103279668A (en) * | 2013-05-31 | 2013-09-04 | 浙江大学 | Quantitative evaluation system for cancer chemoradiotherapy standard conformity |
| CN106372428A (en) * | 2016-08-31 | 2017-02-01 | 杭州逸曜信息技术有限公司 | Detection method of untoward effect information of medicine clinic abnormal indexes |
| CN106874677B (en) * | 2017-02-20 | 2020-05-19 | 上海智眠信息科技有限公司 | Remote auxiliary medical method and device and medical advice platform system |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112349371A (en) * | 2020-11-18 | 2021-02-09 | 南通市第一人民医院 | Chemotherapy patient drug record evaluation method and device |
| CN119361072A (en) * | 2024-12-27 | 2025-01-24 | 山东衡昊信息技术有限公司 | An electronic management system and method for the treatment process and follow-up of childhood malignant tumors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fried et al. | The insertion and management of external ventricular drains: an evidence-based consensus statement: a statement for healthcare professionals from the Neurocritical Care Society | |
| CN108877954B (en) | A method for assessing medication adherence | |
| Lathia et al. | Evaluation of direct medical costs of hospitalization for febrile neutropenia | |
| CN106485403A (en) | Hospital evaluation system and evaluation method based on medical big data | |
| Ziai et al. | A randomized 500-subject open-label phase 3 clinical trial of minimally invasive surgery plus alteplase in intracerebral hemorrhage evacuation (MISTIE III) | |
| JP6059800B2 (en) | Healthcare information processing system | |
| CN119361072A (en) | An electronic management system and method for the treatment process and follow-up of childhood malignant tumors | |
| Hwang et al. | Mapping Korean EDI Medical Procedure Code to SNOMED CT. | |
| Khatri et al. | Variation in emergency department visit rates for opioid use disorder: implications for quality improvement initiatives | |
| CN109008959A (en) | Internal Medicine-Oncology chemotherapy side effect intelligent decision system | |
| CN120199389A (en) | A benefit-risk assessment technology system for post-marketing Chinese patent medicines | |
| EP2339488A1 (en) | A system for analysis and report of drug interactions | |
| Lee et al. | Exploring the subjective frame of patient satisfaction among patients admitted to the comprehensive nursing care service: Q methodology application | |
| Chen et al. | Construction and application of nasopharyngeal carcinoma-specific big data platform based on electronic health records | |
| Dawson et al. | Inpatient warfarin management: pharmacist management using a detailed dosing protocol | |
| Sagreiya et al. | The utility of general purpose versus specialty clinical databases for research: warfarin dose estimation from extracted clinical variables | |
| CN120032794B (en) | Monitoring and management system for rational use of antimicrobial drugs based on the whole process of clinical pathway | |
| CN115458119A (en) | Prescription commenting method for refined antibacterial drugs | |
| KR102844794B1 (en) | AI-based apparatus for removing duplicate data in healthcare benefit pre-assessment and estimating pharmaceutical market size | |
| Strohecker | Polished automation tools allow patient safety to shine | |
| Ma et al. | Commercial health insurance–a new power to push china healthcare reform forward? | |
| Jaworski et al. | Supporting Doctor’s Decisions Based on Electronic Medical Documentation in Polish | |
| Alhusain et al. | D-19| Elevated Troponin Predicts Death and In-Hospital Complications in COVID-19 patients: A Systematic Review and Meta-Analysis | |
| Bao et al. | HSD10 Medical Cannabis Legalization and Opioid-and Pain-Related Outcomes Among US Patients Newly Diagnosed With Cancer and Receiving Anti-Cancer Treatment | |
| KAMADA et al. | Evaluation of the Clinical Benefit of a G-CSF Biosimilar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181218 |